Angiogenic Switch in Patients With Colorectal Cancer

Sponsor
Grupo Hospital de Madrid
Study ID
NCT02075086
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

A group of colorectal cancer (CRC) patients treated with chemotherapy and Bevacizumab (Bev) maintain the same sensitivity after progression to maintenance treatment because they remain dependent on VEGF angiogenic mediator, while other patients in whom there is an angiogenic switch (AS) become dependent on other angiogenic cytokines and become resistant to Bev chemotherapy combinations .

Key Dates

First listed
Mar 3, 2014
Start date
Jul 31, 2011
Status verified
Mar 2015
Primary completion
May 31, 2015
Completion
May 31, 2015

Study Design

Enrollment
100 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Chemotherapy treatment
    Chemotherapy treatment with Xelox or Xeliri and bevacizumab

Primary Outcome Measure

Progression Free Survival [ Time Frame: 1 year ]

Related Studies